AI Article Synopsis
- Melanoma cases are rising globally, but survival rates remain low due to a lack of effective treatments for advanced stages.
- Apoptosis deficiency in melanoma cells is a significant reason for their resistance to therapy.
- Researchers have identified key proapoptotic proteins and death ligands that could help trigger apoptosis in melanoma, with potential applications in new gene therapies using modified adenoviral vectors.
Article Abstract
In the last decades melanoma incidence has been increasing worldwide, while mortality remained on a high level. Until now, there is no suitable therapy for metastasized melanoma, which could lead to a significant increase in overall survival. Apoptosis deficiency is supposed to be a critical factor for therapy resistance, and previous work has characterized the basic mechanisms of apoptosis regulation in melanoma. Genes and strategies suitable for efficient induction of apoptosis in melanoma cells were identified, which are based on proapoptotic Bcl-2 proteins (Bcl-x(S), Bcl-x(AK), Bik/Nbk and Bax) as well as on tumor necrosis factor (TNF)-related death ligands (CD95L/Fas ligand and TNF-related apoptosis-inducing ligand, TRAIL). Proapoptotic genes may be employed in improved gene therapeutic strategies, based on conditional oncolytic adenoviral vectors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0625.2007.00655.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!